– CANADA, Mississauga – HDAX Therapeutics, Inc., a pharmaceutical company developing therapeutics for neurological and cardiac diseases, today announced the appointment of Dr. Roman Fleck (Ph.D.) as Executive Chairman of the Board of Directors and Dr. Neal Muni (M.D., MSPH) as an Independent Director.
About Dr. Roman Fleck
Dr. Fleck currently serves as the CEO of Janpix, Inc., now a Centessa Pharmaceuticals company, an oncology-focused discovery and development company. He also serves as the Chairman of Omniose, a bacterial vaccine discovery company. Previously, he was a Venture Advisor/Partner with Medicxi Ventures following his role as a Principal where among others he invested in and represented Medicxi Ventures on the boards of GlycoVaxyn (sold to GSK), Versartis (NASDAQ: VSAS), and Novocure (NASDAQ: NVCR). Earlier he was also involved in Funxional Therapeutics and Micromet. Before his venture career, he worked at Boehringer Ingelheim where he led drug development projects in oncology, inflammation, and cardiovascular disease, advancing several compounds from the pre-clinical to clinical stage.
Dr. Roman Fleck received a Ph.D. from MIT and an MBA from NYU Stern.
About Dr. Neal Muni
Dr. Muni brings over 20 years of broad industry experience as an operator, investor, board mem,ber and advisor to multiple biotechnology and pharmaceutical companies. Dr. Muni currently serves as the Managing Director of RTK Group, a biopharmaceutical advisory and investment practice focused on supporting clinical-stage companies from development to commercialization. Dr. Muni also serves as the COO of Comera Life Sciences (NASDAQ: CMRA) and CMO of Unravel BioscienceBefore to that, Dr. Muni was the CEO of Azurity Pharmaceuticals. Dr. Muni maintains staff appointments as Instructor in Medicine and Associate Physician at Harvard Medical School and Brigham and Women’s Hospital and is appointed as a Visiting Scholar at The Wyss Institute of Harvard University.
About HDAX Therapeutics
HDAX is a privately-held, therapeutics-focused company developing first-in-class, small-molecule therapeutics for neurological and cardiac indications resulting from microtubule dysfunction. HDAX’s drug discovery platform is focused on HDAC6, a relevant target for disease modification in chemotherapy-induced peripheral neuropathy and other neuropathies and neurodegenerative disorders, presenting the opportunity to be a first-in-class treatment.
For more information: https://www.hdaxtx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
